Equity Profile

PTGX

Protagonist Therapeutics, Inc.

Health CareBiotechnology$9.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Protagonist Therapeutics, Inc. (PTGX) is a biotechnology company focused on developing novel therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PTGX Q2-2026 Earnings Preview

Context

Company Snapshot

Protagonist Therapeutics, Inc. (PTGX) is a biotechnology company focused on developing novel therapies for serious diseases. With a market cap of $10 billion, it operates in the health care sector, which is increasingly important as the demand for innovative treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+397.37%

Avg Stock Reaction

-0.19%

Last Quarter Recap

In Q1-2026, Protagonist reported an EPS of $0.05, significantly beating expectations of a loss of $0.65. However, the stock experienced a slight decline the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key drug candidates.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding future developments.

Expectations

Wall Street Expectations

Overall, expectations for PTGX are mixed as the company has shown volatility in its earnings history. Investors are keen to see if the positive EPS surprise can be sustained.

Bull Case

If PTGX can continue to deliver positive surprises in earnings and show strong revenue growth, it could drive the stock higher as confidence in its pipeline builds.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of operational challenges, it could lead to a significant decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026?

Given the company's recent surprise in EPS, this figure will be crucial in determining investor sentiment and stock movement.

How is the pipeline of drug candidates progressing?

Updates on clinical trials and drug development will be key indicators of future revenue potential and overall company health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate PTGX's ability to capitalize on its recent positive EPS surprise, as the company has a strong pipeline that could drive future growth.

Supporting Evidence

The recent EPS surprise of +107.67% indicates potential for sustained profitability.

Options pricing suggests a significant move, which may not align with the cautious sentiment reflected in stock performance.

The company's commitment to improving operational efficiency could lead to better-than-expected results.

Key Risk

If the EPS comes in above $0.10, it could challenge the current cautious outlook and shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether PTGX can maintain its recent positive momentum or if it will revert to previous losses.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.00 would support the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±18.21%

Historical Avg

±1.3%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±18.2% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.0%

Calls (18K)P/C Ratio: 2.50Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If PTGX beats expectations, history suggests the stock could rise around 1.27% on the day, confirming confidence in its growth strategy.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of approximately 0.80%, reflecting investor disappointment and concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key drug candidates.
2Any guidance on expected revenue growth for the upcoming quarters.
3Details on operational efficiency improvements and cost management.
4Management's outlook on market conditions and competitive landscape.
5Responses to analyst questions regarding long-term growth strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Protagonist Therapeutics, Inc. (PTGX) is a biotechnology company focused on developing novel therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PTGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+397.37%

Avg Stock Reaction

-0.19%

Last Quarter Recap

In Q1-2026, Protagonist reported an EPS of $0.05, significantly beating expectations of a loss of $0.65. However, the stock experienced a slight decline the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key drug candidates.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding future developments.

Expectations

Wall Street Expectations

Overall, expectations for PTGX are mixed as the company has shown volatility in its earnings history. Investors are keen to see if the positive EPS surprise can be sustained.

Bull Case

If PTGX can continue to deliver positive surprises in earnings and show strong revenue growth, it could drive the stock higher as confidence in its pipeline builds.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of operational challenges, it could lead to a significant decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026?

Given the company's recent surprise in EPS, this figure will be crucial in determining investor sentiment and stock movement.

How is the pipeline of drug candidates progressing?

Updates on clinical trials and drug development will be key indicators of future revenue potential and overall company health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate PTGX's ability to capitalize on its recent positive EPS surprise, as the company has a strong pipeline that could drive future growth.

Supporting Evidence

The recent EPS surprise of +107.67% indicates potential for sustained profitability.

Options pricing suggests a significant move, which may not align with the cautious sentiment reflected in stock performance.

The company's commitment to improving operational efficiency could lead to better-than-expected results.

Key Risk

If the EPS comes in above $0.10, it could challenge the current cautious outlook and shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether PTGX can maintain its recent positive momentum or if it will revert to previous losses.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.00 would support the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±18.21%

Historical Avg

±1.3%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±18.2% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.0%

Calls (18K)P/C Ratio: 2.50Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If PTGX beats expectations, history suggests the stock could rise around 1.27% on the day, confirming confidence in its growth strategy.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of approximately 0.80%, reflecting investor disappointment and concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key drug candidates.
2Any guidance on expected revenue growth for the upcoming quarters.
3Details on operational efficiency improvements and cost management.
4Management's outlook on market conditions and competitive landscape.
5Responses to analyst questions regarding long-term growth strategies.